

ANNEX 2 – INSTRUCTIONS FOR TECHNICAL PROPOSALS AND OFFERS

This section is intended to ensure that technical dossiers are submitted in a manner that they can be easily identified, stored, retrieved and assessed in an efficient manner. All technical documents MUST be UPLOADED to a UNICEF SharePoint¹ site as per instructions in **Annex 3 Instructions for uploading Technical Documents to SharePoint**. For your SharePoint site to be established, send email to Martina Tonin Podobnikar at mpodobnikar@unicef.org with full name and address of bidder and INN descriptions of products of interest.

1. UNICEF Technical Questionnaire for Pharmaceutical Manufacturers:

All bidders shall fill in the UNICEF Technical Questionnaire for manufacturers (Annex 2a). Fill in One Technical Questionnaire per manufacture SITE from where FPPs offered are manufactured.

2. UNICEF Technical Questionnaire for Pharmaceutical Wholesalers:

Wholesalers and distributors shall fill in the UNICEF Technical Questionnaire for wholesalers (Annex 2b). The bidder must provide evidence that they are authorized by the FPP manufacturer and/or marketing authorization holder to offer their product(s) in UNICEF tender.

3. Interagency Finished Pharmaceutical Product Questionnaire (IAFPPQ):

Bidders are required to fill in the electronic Interagency Finished Pharmaceutical Product Questionnaire (Annex 2c) if:

- Product is manufactured and/or supplied from Non-ICH countries with no marketing authorization from an International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) regulatory member competent authority
- Product is manufactured and/or supplied from Non-Pharmaceutical Inspectorate Cooperation Scheme (PIC/S) countries
- Product is manufactured and/or sourced from an ICH or PIC/S country, but the product does not have marketing authorization in that country or is registered "FOR EXPORT ONLY"
- UNICEF has limited or no prior procurement experience of the product(s) irrespective of country of manufacture or marketing authorization status.

Fill in ONE Interagency Finished Pharmaceutical Product Questionnaire per Finished Pharmaceutical Product (FPP) offered.

- Documents submitted as Annexes to the Interagency Finished Pharmaceutical Product Questionnaire should be in PDF format and should be well indexed, labelled and organized as instructed in **Annex 3 Instructions for uploading Technical documents to SharePoint**
- Section 5 of the IAFPPQ Commitment and signature page (Annex 2d). This section contains the signed commitment and authorisation related to the product for which the Interagency Finished Pharmaceutical Product Questionnaire is submitted for. It must be submitted for each offered FPP/ Interagency Finished Pharmaceutical Product Questionnaire.

IMPORTANT: The Interagency Finished Pharmaceutical Product Questionnaire (Annex 2c) is a PDF form that must be filled in correctly in line with the documents/data submitted as Annexes (per Section 6-Checklist for Annexes and attachments of the Interagency Questionnaire) and other relevant documentation. The filled in PDF form will be a key document used in UNICEF's technical evaluation for each product. The completed PDF form must be returned in the exact same PDF format. (Do NOT print or scan, do not fill in with pen, do not include pictures).

4. UNICEF API declaration form (Annex 2e) must be filled in by FPP manufacturer and completed for each API used for manufacture of each FPP offered in this tender. Fill in ONE API declaration form for each API validated for use in the FPP.

5. UNICEF Technical offer form (Annex 2f) and the UNICEF Technical commitment declaration form (Annex 2g)

Bidders shall fill in the UNICEF Technical offer form and UNICEF Technical commitment declaration form if:

- Product has been technically assessed by UNICEF in the preceding 5 years and accorded an unqualified "acceptable" status with no quality issues during that period;

¹ Request an option for Cloud based file transfer ONLY if it is not feasible to upload documents in SharePoint

- b. Product has been assessed by UNICEF in the preceding 3 years and accorded a qualified or conditional “acceptable” status and the qualified or conditional acceptance status resolved;
- c. Product has Marketing Authorization from a Stringent Regulatory Authority (SRA)/WHO Listed Authority (WLA)²
- d. Product has Marketing Authorization from a regulatory authority that is PIC/S member for products manufactured in their own country. IAFPPQ (Annex 2c) is required if UNICEF has limited or no prior procurement experience from the manufacturing site in that PIC/S country.
- e. Product(s) and manufacture site(s) has been technically assessed and approved by the partners below
 - i. World Health Organization prequalification programme, <https://extranet.who.int/prequal/>
 - ii. WHO conducted Expert Review Panel (ERP)
 - iii. Médecins Sans Frontières (MSF) International
 - iv. Other agencies included in the IAFPPQ

Note: The bidder is required to sign a Letter of Authorization permitting UNICEF access to information from WHO, ERP, MSF etc. (Annex 2i)

6. Clarifications and additional information

The bidder may be requested to clarify or provide additional information and/or documentation to facilitate technical evaluation.

7. About all technical documents

- Documents that are NOT originally in English language MUST be accompanied by an accurate professional English translation and certified as a true translation of the original
- No handwritten documents will be accepted
- All documents/filled forms shall have no interlineations, erasures, or overwriting. Any necessary corrections shall be initialled by the person or persons signing the bid

8. Naming of Annexes and Attachments of the Interagency Finished Pharmaceutical Product Questionnaire:

[Annex 2a UNICEF Technical questionnaire for pharmaceutical manufacturers](#)

[Annex 2b UNICEF Technical Questionnaire for pharmaceutical wholesalers](#)

[Annex 2c Interagency Finished Pharmaceutical Product Questionnaire \(IAFPPQ\)](#)

[Annex 2d IAFPPQ Commitment and signature - Section 5](#)

[Annex 2e UNICEF API Declaration form](#)

[Annex 2f UNICEF Technical Offer form](#)

[Annex 2g UNICEF Technical commitment declaration form](#)

[Annex 2i Letter of Authorization permitting UNICEF access to information from WHO, ERP, MSF etc.](#)

Annex A Batch Formula

Annex B Primary Packaging

Annex C Secondary Packaging

Annex D CPP

Annex E MA issued & approval history

Annex F Acceptance letter issued by WHO PQ/SRA/WLA

Annex G Product Photos

Annex H Label-Primary

Annex I Label-Secondary

Annex J SmPC and PIL

Annex K API GMP certificate and Manufacturing License

Annex L API specification (FPP Mfg. Internal spec)

Annex M Method Validation for API

Annex N CEP/WHO PQ certificate

Annex O Technical file (DMF)

Annex P Data on validation of sterile API

Annex Q API COA (API Mfg. & FPP Mfg.)

² 1) A member of International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) prior to 23 October 2015, namely: the US Food and Drug Administration, the European Commission and the Ministry of Health, Labour and Welfare of Japan also represented by the Pharmaceuticals and Medical Devices Agency; or 2) an ICH observer prior to 23 October 2015, namely: the European Free Trade Association, as represented by Swissmedic and Health Canada; or 3) a regulatory authority associated with an ICH member through a legally-binding, mutual recognition agreement prior to 23 October 2015, namely: Australia, Iceland, Liechtenstein and Norway

Annex R API source comparison
Annex S FPP GMP certificate and Manufacturing License
Annex T FPP Specifications (release & shelf life)
Annex U FPP CoA (3 Batches)
Annex V Process Flow Diagram (FPP mfg. process)
Annex W Process validation report
Annex X Data on validation of sterile aspects for sterile FPP
Annex Y Nitrosamines risk assessment
Annex Z Stability Data
Annex Z1 Status of On-going Stability
Annex AA Stability Declaration (API used)
Annex AB In-use Stability Data
Annex AC Summary of pharmacology, toxicology and efficacy of the product
Annex AD Graphic summary of BE results
Annex AE BE study report/CDP study report
Annex AF CRO inspection outcome evidence and certificate of Accreditation of Facility/Laboratory
Annex AG Schematic representation of BE study design
Annex AH Study protocol summary
Annex AI Latest Periodic Safety report
Annex AJ Power of Attorney